TG THERAPEUTICS, INC. TGTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
2.04
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $616.3M | $447.2M | — | -$25.0M | $648.0M |
| 2024 | $329.0M | $23.4M | — | -$40.6M | $222.4M |
| 2023 | $233.7M | $12.7M | — | -$31.4M | $160.5M |
| 2022 | $2.8M | -$223.8M | — | -$176.2M | $58.6M |
| 2021 | $6.7M | -$348.1M | — | -$296.0M | $237.2M |
| 2020 | $152,000 | — | — | -$214.9M | $519.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Charney Laurence N | director | 2026-01-29 | Gift | 13,197 | — |
| Charney Laurence N | director | 2026-01-28 | Gift | 30,000 | — |
| Power Sean A | CFO | 2026-01-08 | Grant | 90,000 | — |
| WEISS MICHAEL S | CEO | 2026-01-08 | Grant | 622,000 | — |
| Echelard Yann | director | 2025-11-24 | Sell | 5,000 | $32.57 |
| WEISS MICHAEL S | CEO | 2025-11-05 | Gift | 3,865,126 | — |
| WEISS MICHAEL S | CEO | 2025-11-05 | Gift | 803,717 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.04 (grey)
- Working capital / assets 0.449
- Retained earnings / assets -1.018
- EBIT / assets 0.116
- Equity / liabilities 1.561
Source: SEC EDGAR filings · CIK 0001001316 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.